JP2017538412A5 - - Google Patents

Download PDF

Info

Publication number
JP2017538412A5
JP2017538412A5 JP2017530686A JP2017530686A JP2017538412A5 JP 2017538412 A5 JP2017538412 A5 JP 2017538412A5 JP 2017530686 A JP2017530686 A JP 2017530686A JP 2017530686 A JP2017530686 A JP 2017530686A JP 2017538412 A5 JP2017538412 A5 JP 2017538412A5
Authority
JP
Japan
Prior art keywords
seq
binding member
variant
amino acid
functional fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017530686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538412A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/059562 external-priority patent/WO2016092524A1/en
Publication of JP2017538412A publication Critical patent/JP2017538412A/ja
Publication of JP2017538412A5 publication Critical patent/JP2017538412A5/ja
Pending legal-status Critical Current

Links

JP2017530686A 2014-12-11 2015-12-11 ヒトc−mafに対する結合メンバー Pending JP2017538412A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462090599P 2014-12-11 2014-12-11
US62/090,599 2014-12-11
PCT/IB2015/059562 WO2016092524A1 (en) 2014-12-11 2015-12-11 Binding members for human c-maf

Publications (2)

Publication Number Publication Date
JP2017538412A JP2017538412A (ja) 2017-12-28
JP2017538412A5 true JP2017538412A5 (enExample) 2019-01-24

Family

ID=55024191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017530686A Pending JP2017538412A (ja) 2014-12-11 2015-12-11 ヒトc−mafに対する結合メンバー

Country Status (10)

Country Link
US (1) US10793642B2 (enExample)
EP (1) EP3229909B1 (enExample)
JP (1) JP2017538412A (enExample)
KR (1) KR20170093182A (enExample)
CN (1) CN107001480B (enExample)
AU (1) AU2015358868A1 (enExample)
BR (1) BR112017012515A2 (enExample)
CA (1) CA2967224C (enExample)
MX (1) MX2017007381A (enExample)
WO (1) WO2016092524A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012045905A2 (es) 2010-10-06 2012-04-12 Fundació Privada Institut De Recerca Biomèdica Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
KR102226219B1 (ko) 2012-06-06 2021-03-10 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 폐암 전이의 진단, 예후 및 치료 방법
JP6074049B2 (ja) 2012-10-12 2017-02-01 インバイオモーション エセ.エレ. c−MAFを用いた前立腺がん転移の診断、予後診断および処置のための方法
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20140314792A1 (en) 2013-03-15 2014-10-23 Institució Catalana De Recerca I Estudis Avançats Method for the diagnosis, prognosis and treatment of cancer metastasis
BR112017012515A2 (en) 2014-12-11 2018-01-02 Inbiomotion S.L. binding members for human c-maf
PL3458610T3 (pl) 2016-05-25 2021-11-22 Inbiomotion S.L. Leczenie raka piersi w oparciu o status c-MAF
BR112020010192A2 (pt) 2017-11-22 2020-10-13 Inbiomotion S.L. tratamento terapêutico de câncer de mama com base no status de c-maf

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5185243A (en) 1988-08-25 1993-02-09 Syntex (U.S.A.) Inc. Method for detection of specific nucleic acid sequences
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
GB9509957D0 (en) 1995-05-17 1995-07-12 Khalil Nasreen Post-translational activation of tgf-›1 involving the tsp-1 receptor cd36
US5814468A (en) 1996-03-27 1998-09-29 Coulter International Corp. Methods of enumerating receptor molecules for specific binding partners on formed bodies and in solution
US5958671A (en) 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
CA2274987C (en) 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) * 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
EE04911B1 (et) 1999-03-15 2007-10-15 Axys Pharmaceuticals, Inc. Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
US6525036B2 (en) 2000-01-06 2003-02-25 Merck & Co., Inc. Compounds and compositions as protease inhibitors
EP1272668B1 (en) 2000-04-03 2007-02-14 Corixa Corporation Methods, compositions and kits for the detection and monitoring of breast cancer
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
DK2087908T3 (en) 2001-06-26 2018-07-23 Amgen Inc ANTIBODIES AGAINST OPGL
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
IL162111A0 (en) 2001-12-22 2005-11-20 4Antibody Ag Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
AU2003286499A1 (en) 2003-10-17 2004-06-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
US20090048117A1 (en) 2003-12-18 2009-02-19 President And Fellows Of Harvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
EP3211086B1 (en) 2005-09-20 2021-06-09 Menarini Silicon Biosystems S.p.A. Methods and composition to generate unique sequence dna probes, labeling of dna probes and the use of these probes
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
AU2007269654B2 (en) 2006-06-30 2013-01-10 University Of Southern California Quantifiable internal reference standards for immunohistochemistry and uses thereof
WO2008086800A2 (en) 2007-01-15 2008-07-24 Aarhus Universitet Predisposition to, prognosis for and treatment of breast cancer relating to human chromosome 16
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
CN101772511A (zh) 2007-02-16 2010-07-07 太平洋艾瑞有限公司 通过影响粘连蛋白质表达阻止癌细胞的转移和新化合物及其应用
US8623361B2 (en) 2007-05-24 2014-01-07 Ablynx N.V. Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
US20110166838A1 (en) 2008-06-16 2011-07-07 Sividon Diagnostics Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
WO2010110346A1 (ja) 2009-03-24 2010-09-30 独立行政法人理化学研究所 白血病幹細胞マーカー
WO2011039734A2 (en) 2009-10-02 2011-04-07 Enzo Medico Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
WO2012045905A2 (es) 2010-10-06 2012-04-12 Fundació Privada Institut De Recerca Biomèdica Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
US20140162887A1 (en) 2011-02-04 2014-06-12 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
EP2650682A1 (en) * 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
KR102226219B1 (ko) * 2012-06-06 2021-03-10 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 폐암 전이의 진단, 예후 및 치료 방법
JP6074049B2 (ja) 2012-10-12 2017-02-01 インバイオモーション エセ.エレ. c−MAFを用いた前立腺がん転移の診断、予後診断および処置のための方法
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
AU2014229505B2 (en) 2013-03-15 2020-02-27 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
US20140314792A1 (en) 2013-03-15 2014-10-23 Institució Catalana De Recerca I Estudis Avançats Method for the diagnosis, prognosis and treatment of cancer metastasis
MX362041B (es) 2013-10-09 2019-01-07 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama.
BR112017012515A2 (en) 2014-12-11 2018-01-02 Inbiomotion S.L. binding members for human c-maf
PL3458610T3 (pl) 2016-05-25 2021-11-22 Inbiomotion S.L. Leczenie raka piersi w oparciu o status c-MAF
BR112020010192A2 (pt) 2017-11-22 2020-10-13 Inbiomotion S.L. tratamento terapêutico de câncer de mama com base no status de c-maf

Similar Documents

Publication Publication Date Title
JP2017538412A5 (enExample)
JP2012526530A5 (enExample)
JP2016536330A5 (enExample)
JP2012525432A5 (enExample)
JP2020522261A5 (enExample)
JP2018121657A5 (enExample)
JP2016029056A5 (enExample)
JP2013060443A5 (enExample)
JP2019513784A5 (enExample)
NL300919I2 (nl) Brodalumab
JP2012012402A5 (enExample)
JP2014506132A5 (enExample)
JP2019507762A5 (enExample)
JP2013506428A5 (enExample)
JP2010523592A5 (enExample)
JP2013507970A5 (enExample)
JP2018516853A5 (enExample)
JP2017532005A5 (enExample)
JP2013538057A5 (enExample)
AR084210A1 (es) PROTEINAS DE UNION AL TNF-a
JP2016500655A5 (enExample)
JP2013544756A5 (enExample)
JP2008529489A5 (enExample)
JP2020536507A5 (enExample)
JP2012523848A5 (enExample)